Cardiopulmonary bypass is characterized by multiple haemostatic defects. These are due to haemodilution, platelet damage, the effects of hypothermia, heparin administration, and, in many patients, preoperative use of aspirin. The result is often excessive blood loss. Pharmacological agents such as desmopressin, prostacyclin, and aprotinin have been introduced to improve haemostasis during cardiopulmonary bypass. The protease inhibitor aprotinin appears to be particularly promising in reduction of bleeding associated with bypass. Study of aprotinin may provide new insights into the mechanisms of haemostatic dysfunction, particularly platelet dysfunction.
Nurden AT, Caen JPMembrane glycoproteins and human platelet function. Br J Haematol1978; 38: 155-60.
3.
Zilla P., Groscurth P., Rhyner K., von Felten A.Surface morphology of human platelets during in vitro aggregation. Scand J Haematol1984; 33: 440-7.
4.
Moncada S., Vane JRPharmacology and endogenous roles of prostaglandins and endoperoxides, thromboxane A2 and prostacyclin. Pharmacol Rev1978; 30293-331.
5.
Aren C., Feddersen K., Rädegran K.Effects of prostacyclin infusion on platelet activation and postoperative blood loss in coronary bypass. Ann Thorac Surg1983; 36: 49.
6.
Parise LVThe structure and function of platelet integrins. Curr Opin Cell Biol1989; 1: 947-52. 7 Mann KG, Tracy PB, Krishnaswamy S., Jenny RJ et al. In: Verstraete M, Vermylen J, Lignen R, Arnout J eds. Thrombosis and haemostasis. Leuven: Leuven University Press, 1987: 505-23.
7.
Prentice Crm, McNicol GP, Douglas ASStudies on the anticoagulant action of aprotinin (Trasylol). Thomb Diath Haemorrh1970; 24: 265-72.
8.
Michelson EL, Morganroth J., Torosian M., MacVaugh H III. Relation of preoperative use of aspirin to increased mediastinal blood loss after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg1978; 78: 694-7.
9.
Ferraris VA , Ferraris SP, Lough FC, Berry WRPreoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting. Ann Thorac Surg1988; 45: 71-4.
10.
Goldman S., Copeland J., Mortiz T. et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation1988; 77: 1324-32.
Harker L., Malpass TW, Branson HE, Hessel EA II, Slichter SAMechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective α-granule release. Blood1980; 56: 824.
13.
Gravlee GP, Haddon WS, Rothberger HK et al. Heparin dosing and monitoring for cardiopulmonary bypass. J Thorac Cardiovasc Surg1990; 99: 518.
14.
Bull BS, Huse WM, Brauer FS, Korpman RAHeparin therapy during extracorporeal circulation. II. The use of dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg1975; 69: 685-9.
15.
Mannucci PMDesmopressin (DDAVP) for treatment of disorders of haemostasis. In: Coller B ed. Progress in haemostasis and thrombosis , Volume 8. New York: Grune & Stratton, 1986: 19-45.
16.
Weksler BBPlatelet interactions with the blood vessel wall. In: Coleman RW, Hirsh J, Marder VJ, Salzman EW eds. Hemostasis and thrombosis, second edition. Philadelphia: Lippincott , 1987: 793.
17.
Hackmann T. , Gascoyne RD, Naiman SC et al. A trial of desmopressin (1-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med1989; 321: 1437.
18.
Rocha E., Llorens R., Paramo JA, Areas R., Cuesta B., Trenor AMDoes desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass? Circulation1988; 77: 1319.
19.
Fish KJ, Sarnquist FH, van Steennis C. et al. A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations. J Thorac Cardiovasc Surg1986; 91: 436-42.
20.
Verstraete M.Clinical application of inhibitors of fibrinolysis . Drugs1985; 29: 236. 22 Lindon JN, McManama G., Kushner L., Merrill EW, Salzman EWDoes the conformation of absorbed fibrinogen dictate platelet interactions with artificial surfaces ? Blood1986; 68: 355-62. 23 Orchard MA, Goodchild C., Prentice Crm et al.. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol (unpublished observations). 24 Bidstrup BP, Royston D., Sapsford RN, Taylor KMReduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol) . J Thorac Cardiovasc Surg1989; 97: 364-72.
21.
Van Oeveren W., Harder MP, Roozendaal KJ, Eijsman L., Wildevuur Crh.Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg1990; 99: 788-97.
